ReviewPain research & management2026
Breaking Through Cancer Pain: From Single-Drug Management to Multimodal Analgesia.
Review in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCancer pain affects 60%-80% of patients with advanced cancer, and approximately 30% of patients experience inadequate pain control. Although the World Health Organization (WHO) three-step analgesic ladder has substantially improved pain management, inadequate analgesia, opioid-related adverse effects, and refractory pain continue to pose significant clinical challenges.
objectiveThis narrative review critically evaluates recent advances in cancer pain management, including novel analgesics, optimized opioid formulations, nanomedicine, invasive interventions (intrathecal drug delivery, neuromodulation, and neurolysis), and complementary integrative therapies, aiming to provide up-to-date insights for clinicians and researchers.
resultsNovel analgesics targeting μ-opioid receptor bias, ion channels, and multitarget strategies have shown preclinical promise. Improved opioid formulations and nanomedicine-based approaches may enhance drug delivery and reduce toxicity. Fourth-step interventions, including intrathecal drug delivery, neuromodulation, and neurolysis, provide targeted options for selected patients with refractory cancer pain. Integrative therapies, including mind-body interventions, acupuncture, massage, music therapy, and game-based approaches, may improve symptom burden and quality of life, although evidence for direct analgesic effects remains limited.
conclusionCancer pain management is evolving toward a multimodal and increasingly personalized framework. Despite substantial progress, many emerging therapies lack robust cancer-specific validation. High-quality clinical trials, standardized treatment protocols, and improved translational strategies are needed to establish evidence-based precision cancer pain management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.